Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 14,922 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disorders Clear all
Withdrawn Phase 4 Interventional

Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy

NCT01386255
View directory record Official record
Conditions
Cerebral Palsy, GERD
Interventions
Baclofen, placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Not applicable Interventional

Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia

NCT02073578
View directory record Official record
Conditions
Achalasia
Interventions
Peroral Endoscopic Myotomy (POEM)
Procedure
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

NCT00096278
View directory record Official record
Conditions
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7
Interventions
Bevacizumab, Fluorouracil, Leucovorin Calcium, Oxaliplatin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 3 Interventional

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

NCT00061815
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
39
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Fountain Valley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2010 · Synced Oct 20, 2026, 1:05 AM EDT
Recruiting Not applicable Interventional

EUS-guided Celiac Plexus Block vs. Sham in Chronic Pancreatitis

NCT06178315
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
EUS-guided celiac plexus block, Sham procedure
Procedure
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 4 Interventional Results available

Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease

NCT01034358
View directory record Official record
Conditions
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Interventions
Human Papillomavirus Vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 20, 2026, 1:05 AM EDT
Recruiting No phase listed Observational

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

NCT01769755
View directory record Official record
Conditions
Crohns Disease
Interventions
PDA001, Vehicle Controlled Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 20, 2026, 1:05 AM EDT
Terminated Phase 1 Interventional

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

NCT01249443
View directory record Official record
Conditions
HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vorinostat, diagnostic laboratory biomarker analysis, pharmacological study, carboplatin, paclitaxel
Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Not applicable Interventional

Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients

NCT00956215
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Aprepitant, Aprepitant placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01020708
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine, ALTH12-1:4, ALTH12-2:4
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 20, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional Results available

Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

NCT02950025
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas, Hepatocellular Carcinoma
Interventions
Online, adaptive MR-guided SBRT, Online, non-adaptive MR-guided SBRT, European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 4 Interventional Results available

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

NCT02339038
View directory record Official record
Conditions
HCV HIV
Interventions
Ledipasvir 90 mg and Sofosbuvir 400 mg
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

NCT01393626
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
73
States / cities
Anaheim, California • Oceanside, California • Poway, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 20, 2026, 1:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Interventions
IDE196, Binimetinib, Crizotinib
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 20, 2026, 1:05 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease

NCT02076438
View directory record Official record
Conditions
Diarrhea
Interventions
Probiotics
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants

NCT05366738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Results available

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

NCT03251378
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Rectal Cancer
Interventions
Fruquintinib (HMPL-013)
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Phoenix, Arizona • San Marcos, California • Santa Rosa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 20, 2026, 1:05 AM EDT
Withdrawn Not applicable Interventional

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

NCT01266785
View directory record Official record
Conditions
Crohn's Disease
Interventions
Infliximab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 1 Interventional

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

NCT04580485
View directory record Official record
Conditions
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
Interventions
INCB106385, INCMGA00012
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
West Hollywood, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

NCT00290615
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, cetuximab, capecitabine, oxaliplatin
Biological · Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

NCT00248625
View directory record Official record
Conditions
Acute Liver Failure, Hepatic Encephalopathy
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Antibiotic "Dysbiosis" in Preterm Infants

NCT02784821
View directory record Official record
Conditions
Enterocolitis, Necrotizing, Bacteremia, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia, Chronic Lung Disease, Ileal Perforation
Interventions
Antibiotic, Gastric fluid, Breast milk, Stool samples, Antibiotics
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
23 Weeks to 33 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 20, 2026, 1:05 AM EDT
Completed Not applicable Interventional Results available

A Study to Improve the FAST Ultrasound Exam

NCT02991521
View directory record Official record
Conditions
Hemoperitoneum
Interventions
Fast exam
Procedure
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 20, 2026, 1:05 AM EDT